Deep Genomics
Latest round
- Series C
Last raised
- Jul 2021
Total raised
- $237M
Investors
- 10
About Deep Genomics
Based in Toronto, Canada, and founded in 2014, Deep Genomics Inc. operates as a biotechnology company that offers an AI-based platform to create and produce clinically evaluating therapies for rare diseases. The company has 50 members and was co-founded by Brendan Frey (CEO) and Hui Yuan Xiong. In July 2021, Deep Genomics Inc. The company provides an AI-based machine learning platform that focuses on transformational RNA therapeutics for genetic diseases. Deep Genomics also provides a platform called AI Workbench, which helps detect and solve problems related to the human genome, genetic variants, and vast amounts of data on RNA biology. AI Workbench focuses on the discovery of novel therapeutic targets for diseases such as Gout, Wilson Disease, Niemann-Pick disease type C (NPC), and Frontotemporal dementia (FTD). Deep Genomics Inc. plans to expand the AI Workbench, scale its pipeline to 30 programs, double its staff to around 160 heads by the end of 2022, and advance four programs into the clinic by 2023.
Who invested in Deep Genomics
10 investors across 4 rounds
See all investors in Deep Genomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Deep Genomics
Who invested in Deep Genomics?
Deep Genomics has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Deep Genomics raised?
Deep Genomics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Deep Genomics last raise money?
Deep Genomics's most recent round on record is a Series C, in Jul 2021.
What does Deep Genomics do?
Based in Toronto, Canada, and founded in 2014, Deep Genomics Inc.
Where is Deep Genomics headquartered?
Deep Genomics is headquartered in Toronto, Canada.
Which VCs invest in companies like Deep Genomics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Deep Genomics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Deep Genomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.